|
Stock Analysts’ Ratings Reiterations for July, 1st (AMP, BBRY, BIIB, COH, CRM …
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
Hindustan Times – Hindustan Times
Hindustan TimesHindustan TimesWith reference to the report Donate: gift a life (June 30), it is appalling that even as India is making rapid strides in the development of science and technology, people in our country are reluctant to pledge their organ…
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market … – Sacramento Bee
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …Sacramento BeeThe currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the …
Biogen Idec Stock Rating Reaffirmed by Piper Jaffray (BIIB) – Zolmax
|
Biogen Idec Stock Rating Reaffirmed by Piper Jaffray (BIIB)
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
DUBLIN, July 1, 2013 /PRNewswire/ — – PR Newswire (press release)
DUBLIN, July 1, 2013 /PRNewswire/ –PR Newswire (press release)The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selli…
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies – PR Newswire UK (press release)
Competitor Analysis: Biosimilar and Biosuperior Therapeutic AntibodiesPR Newswire UK (press release)This report provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next gen…
UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors – Benzinga
|
UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors
Benzinga … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
Heart-break causes more suicides than unemployment: NCRB report – Daily News & Analysis
|
Heart-break causes more suicides than unemployment: NCRB report
Daily News & Analysis More people in India end their lives due to heart-break than unemployment or bankruptcy/sudden change in the economic status according to the National Crime Records Bureau (NCRB) ‘Accidental Deaths and Suicides in India 2012′ report. Not only that … |
Dr Reddy's Laboratories launches online repositories on lung and breast cancer – Economic Times
Economic Times |
Dr Reddy’s Laboratories launches online repositories on lung and breast cancer
Economic Times … repositories dedicated to lung and breast cancer studies related to India. The repositories will have information collected from various sources, published and unpublished on lung and breast cancer studies specific to India, the company said in a … Dr Reddy’s launches online repositories on lung, breast cancersHindu Business Line Dr. Reddy’s partners with leading oncologists in furthering awareness on Lung …India PRwire (press release) Dr Reddy ties up with Shvaas and IBCR for lung & breast cancer awareness in …pharmabiz.com Business Standard all 87 news articles » |
Diabetes, heart diseases boost olive oil demands in India – Daily News & Analysis
Daily News & Analysis |
Diabetes, heart diseases boost olive oil demands in India
Daily News & Analysis “Main driving factor for olive oil demands in India is health-related problems like increasing cases of diabetes, hypertension and heart diseases,” VN Dalmia, president of the Indian Olive Association, said. He said in 2012-13, growth in import of … |